Swoop, a New York company that runs data-driven marketing and engagement programmes for the pharmaceutical industry, acquired Nimble, a prescription management and fulfillment platform used by independent pharmacies, Swoop announced on 26 May 2026.
Terms were not disclosed. Swoop's announcement gave no price or deal structure, and the trade press coverage did not report one.
Nimble will operate as a Swoop company. Swoop said pharmacies on the platform would gain stronger patient engagement from Swoop's reach and resources, and that patients would get more consistent support. Talha Sattar, Nimble's founder and chief executive, was quoted in the announcement.
What Nimble built
Nimble works with independent pharmacies in all 50 US states. Its software lets patients fill, refill, pay for and manage prescriptions online, and gives pharmacies tools for mobile checkout and patient messaging. Swoop says 16 million patients use it, and that Nimble's digital interventions improve medication adherence by 26% to 40%.
The company started out differently. When it raised $28 million in 2017, CNBC described Nimble Pharmacy as a same-day prescription delivery service with its own retail stock of medicines, operating in the San Francisco Bay Area and San Diego and competing with startups such as Alto Pharmacy and NowRx. A key feature at the time let patients schedule delivery while still at the doctor's office. By the time of the acquisition, Swoop described Nimble as a technology platform serving independent and regional pharmacies, helping them modernise their workflows.
“Independent pharmacies are where patient care gets real — they're the last mile between a prescription and a patient who actually stays on therapy.”
Why Swoop is buying
Swoop builds audiences of patients and healthcare professionals for drug brands and runs campaigns across channels, along with community and web products. Rines said aggregated signals about patient needs could help consumers move beyond awareness to action, and Nimble gives Swoop a view of what happens at the pharmacy counter.
Swoop chief executive and co-founder Ron Elwell said Nimble would help connect the signals that shape patient and physician behaviour to real-world action, and that the deal took Swoop's platform beyond engagement to impact. President Scott Rines said Nimble extends Swoop into prescription fulfillment and adherence.
Nimble's fulfillment data will feed into what Swoop calls a commercial intelligence layer for life sciences companies. Swoop said these signals are aggregated, privacy-safe and consented, and that drug makers will use them to speed up adoption of therapies and measure real-world outcomes.
Rines added that bringing real-time pharmacy signals into Swoop's broader engagement system would help life sciences companies deliver stronger health and commercial outcomes.
The founder and the funding
Sattar told CNBC in 2017 that he came up with the idea while waiting in a pharmacy line to collect medicine for a family member, and that he saw an information gap between the pharmacy, the physician and the consumer. He had previously worked in finance and management consulting. CNBC reported that Nimble was founded in 2015.
By late 2017, Nimble claimed relationships with one in four doctors in the Bay Area and said it had dispensed 5 million medication doses, a fifth of them in the previous three months, according to CNBC. It planned to use that year's funding to expand into other states.
The 2017 round of $28 million was led by Sequoia Capital, with Y Combinator, First Round Capital, DAG Ventures and Khosla Ventures also among Nimble's investors. Later funding and Nimble's headcount were not reported in the sources reviewed.
In the acquisition announcement, Sattar described independent pharmacies as the last mile between a prescription and a patient who stays on therapy, and said joining Swoop would give them an edge in closing that gap.
About Swoop
Swoop is majority owned by private equity firm New Mountain Capital and was spun off in 2024 from Real Chemistry, another New Mountain company, O'Dwyer's reported. After the Nimble deal, Swoop's portfolio covers audience intelligence, community engagement, AI-powered web products, coordinated omnichannel campaigns and prescription management.
Swoop said it plans to connect its marketing channels for healthcare professionals and patients, and to feed real-time pharmacy signals into its wider engagement system, with the aim of giving life sciences clients measurable commercial results alongside better patient outcomes.
